<DOC>
	<DOCNO>NCT01300351</DOCNO>
	<brief_summary>The purpose study evaluate efficacy new dose 500mg Fulvestrant standard dose 250mg Chinese postmenopausal woman oestrogen receptor positive advanced breast cancer fail prior endocrine treatment .</brief_summary>
	<brief_title>Comparing Efficacy Tolerability Fulvestrant 500 mg Versus 250 mg Advanced Breast Cancer Women</brief_title>
	<detailed_description>Fulvestrant , dose 250mg every 28 day , first oestrogen receptor antagonist agonist effect show least effective TTP ( Time Progression ) OR ( Objective Response ) third-generation aromatase inhibitor second-line treatment advance breast cancer ( Howell et al 2002 , Osborne CK et al 2002 ) .In study overall survival also similar fulvestrant anastrozole treatment arm ( Pippen J et al 2003 ) . Fulvestrant receive approval 70 country worldwide dose regimen . However , evidence number study suggest high dose may able enhance efficacy : - Data Study 0036 ( Addo S et al , 2002 ) suggest dose-response relationship may exist . In female volunteer give single intramuscular ( i.m . ) injection fulvestrant ( 250mg , 125mg placebo ) , dose-dependent inhibition ethinyloestradiol-induced endometrial thicken see Day 28 . - Results short term exposure fulvestrant Studies 0002 ( DeFriend D et al 1994 ) 0018 ( Robertson et al 2001 ) show expression ER , progesterone receptor ( PgR ) cell proliferation-related antigen Ki67 reduce dose-dependent manner . - Data Studies 0020 ( Howell et al 2002 ) 0021 ( Osborne CK et al 2002 ) suggest dose-response effect exist fulvestrant . Fulvestrant 250mg show superior fulvestrant 125mg , discontinue fail meet minimum efficacy requirement . - Evidence pharmacokinetic modelling indicate fulvestrant 500 mg dose regiment achieve high steady state plasma concentration compare fulvestrant 250mg steady state concentration achieve earlier fulvestrant 250mg . - Data Study CONFIRM ( A Di Leo et al 2009 ) , phase III randomise parallel-group trial , demonstrate fulvestrant 500mg offer statistically significant long TTP compare fulvestrant 250mg ( median TTP : 6.5 month vs. 5.5 month ; hazard ratio=0.80 [ 95 % CI 0.68 0.94 ] ; P=0.006 ) , seem consequence increase rate , prolongation duration , disease stabilization . The 50 % event overall survival analysis also seem favour fulvestrant 500mg , although statistical significance reach ( hazard ratio=0.84 [ 95 % CI 0.69 1.03 ] ; P=0.091 ) . The safety analysis raise relevant concern relation fulvestrant 500mg . Therefore , study compare Fulvestrant 500mg fulvestrant 250mg Chinese population order understand optimal dose Chinese patient breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Postmenopausal woman define woman stop menstrual period Breast Cancer continue grow receive treatment antiestrogen hormonal treatment tamoxifen aromatase inhibitor Requiring hormonal treatment Oestrogenreceptor positive tumour Written inform consent participate trial Treatment investigational nonapproved drug within one month An exist serious disease , illness , condition prevent participation compliance study procedures A history allergy active inactive ingredient fulvestrant ( i.e . castor oil ) Treatment one regimen chemotherapy advance breast cancer Treatment one regimen hormonal treatment advance breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>